Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors

Conditions

• Clinical Stage III Cutaneous Melanoma AJCC v8
• Clinical Stage III Gastric Cancer AJCC v8
• Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
• Clinical Stage IV Cutaneous Melanoma AJCC v8
• Clinical Stage IV Gastric Cancer AJCC v8
• Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
• Locally Advanced Gastric Adenocarcinoma
• Locally Advanced Gastroesophageal Junction Adenocarcinoma
• Locally Advanced Urothelial Carcinoma
• Metastatic Gastric Adenocarcinoma
• Metastatic Gastroesophageal Junction Adenocarcinoma
• Metastatic Head and Neck Squamous Cell Carcinoma
• Metastatic Lung Non-Small Cell Carcinoma
• Metastatic Malignant Solid Neoplasm
• Metastatic Melanoma
• Metastatic Urothelial Carcinoma
• Recurrent Head and Neck Squamous Cell Carcinoma
• Refractory Lung Non-Small Cell Carcinoma
• Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
• Stage IV Lung Cancer AJCC v8
• Unresectable Malignant Solid Neoplasm
• Unresectable Melanoma

Interventions

• BIOLOGICAL: Pembrolizumab
• DRUG: Sonidegib

Sponsor

Mayo Clinic